A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The goal of this clinical trial is to investigate how GLP-1 receptor analogs, such as semaglutide (Wegovy®), influence processes that determine eating behavior, binge eating, and weight regulation via the gut-brain axis. The main question it aims to answer is: to identify for whom semaglutide works best. Participants will: * undergo a semaglutide treatment for 6 months * visit the clinic for 2-4 study checkup and tests * wear a smartwatch and complete questionnaires on their smartphone
Epistemonikos ID: fc1c7de8ee29f7dcf0baf008caf60ce041d3997c
First added on: Oct 14, 2026